On March 20, 2023, TBD Pharmatech proudly hosted the bright minds of BÜS – a student organization from Tartu University that unites natural sciences students. BÜS aims to empower future biologists…
Read moreTBD Pharmatech is excited to announce that we will be attending CPHI North America 2023, one of the most important events in the pharmaceutical industry. Our Chief Business Officer, Olga Tšubrik, will…
Read moreMarch 20-23 2023 TBD Pharmatech will be present at DCAT Week 2023! This is the first time TBD Pharmatech is attending DCAT Week. We are already looking forward to discuss CDMO collaboration! Book a…
Read more
Inactive pharmaceutical ingredients (IPIs) are ingredients found in medication that do not directly affect the treatment of a disease or condition. While they may not be active, these components can…
Read more
TBD Pharmatech worked on a PET-diagnostics project together with Latvian partner SIA PharmIdea from 2017 until 2019. The main objective of the Project was to develop a PET-product used in Positron emission…
Read more
On 21st February 2023, the Latvian Institute of Organic Synthesis (LIOS) and TBD Pharmatech signed the Memorandum of Understanding to strengthen the drug manufacturing performance of the Baltic region….
Read more
Ravimainete arendaja ja tootja, mis pakub peenkeemia lahendusi farmaatsia- ja biotehnoloogia ettevõttetele.
